Do you want to read an article? Please log in or register.
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
Pulmonary FibrosisFurther Publications
Related content
RECOMMENDED
Pulmonary Fibrosis
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(24)00208-X
RECOMMENDED
Further Publications
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M, VX17-445-105 Study Group
doi: 10.1164/rccm.202411-2231OC
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
RECOMMENDED
Pulmonary Fibrosis
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Thorax
Maher RE, Cytlak-Chaudhuri UM, Aleem S, Barry P, Brice DP, Caamaño Gutiérrez E, Driver K, Emmott E, Rothwell A, Smith E, Travis M, Lee D, McNamara PS, Waller I, Smith JA, Jones A, Lord RW
doi: 10.1136/thorax-2024-222242
RECOMMENDED
Pulmonary Fibrosis
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A
doi: 10.1016/S2213-2600(24)00411-9
RECOMMENDED
Pulmonary FibrosisPneumonia
Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Dhochak N, Lodha R, Jat KR, Iqbal J, Kumar P, Goyal JP, Varkki S, Kabra SK, CF study group in alphabetical order with equal contribution
doi: 10.1016/j.rmed.2025.108087
RECOMMENDED
Pulmonary Fibrosis
BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Fathima P, Pan E, Marsh J, Newall N, Meares T, McLeod C, Shanthikumar S, Jaffe A, Tai A, Ward N, Sivam S, Selvadurai H, Schultz A, Snelling T
doi: 10.1016/j.rmed.2025.108080
RECOMMENDED
Pulmonary Fibrosis
Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Caley LR, Gillgrass L, Zagoya C, Saumtally H, Duckstein F, H W, Mainz JG, Peckham DG
doi: 10.1016/j.jcf.2025.01.010
Pulmonary Fibrosis
Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes
Respir Med
Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V
doi: 10.1016/j.rmed.2025.108221